Efficacy of lincomycin against the strains of Staphylococcus aureus isolated from various types of pyodermas in children : in vitro and in vivo study.
Lincomycin is chemically distinct from all other available antibiotics except its semi-synthetic derivative clindamycin. Though it has been in the market for over three decades, there were not many clinical studies in India. This study has been undertaken to know its efficacy against Staphylococcus aureus, commonest organism of pyodermas in children. Material was taken from the lesions of 100 fresh cases of various types of pyodermas in children and studied by Gram stain and in 50% human blood agar and nutrient agar according to standard methods. The staphylococci thus isolated were tested for linocomycin susceptibility by using the disc diffusion technique. Lincomycin was given to all these children in a daily dose of 30 mg/kg 5 - 10 days. Treatment failure was defined as persistence of lesions after 10 days of treatment. 75% strains of staphylococci were susceptible to lincomycin in vitro and 95% of the patients responded to 5-10 days treatment. Five out of 100 children did not respond to treatment even after 10 days. No case of relapse was noticed among these 95 children for a period of 2 weeks. No side effects were observed and the drug was very well tolerated. Being highly effective and least toxic linomycin deserves a place in the antimicrobial arsenal of the modern dermatologists.